Glenmark, Company

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India.The PMS study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients. A total of 1083 patients were enrolled in the prospective, open label, multicentre, single arm study.Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects such as weakness, gastritis, diarrhoea, vomiting, etc., were found to be mild in nature. The time for fever resolution was 4 days, while time for clinical cure was 7 days.Glenmark's PMS study is the first and largest post marketing study conducted in India on Favipiravir in mild to moderate COVID-19 patients. Thirteen sites - both Government and private institutions - across Mumbai, Bangalore, Hyderabad, Nashik, Nagpur, and Trivandrum took part. The study was conducted in patients in line with the approved indication of the drug.Commenting on these findings, Alok Malik, Group Vice President & Head, India Formulations, said, "This study was crucial as it examined the safety and efficacy of FabiFlu® in real-world settings, where multiple variables can impact the results. Despite these factors, the PMS study demonstrated FabiFlu®'s consistent ability to provide symptomatic relief and improve clinical outcomes in patients with mild to moderate COVID-19. It is a step forward both for Glenmark and the medical community, as it reinforces the oral antiviral's multiple benefits in tackling the pandemic."On June 19, 2020, Glenmark became the first company in India to receive restricted emergency use approval from India's drug regulator for Favipiravir (FabiFlu®), making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19. The approval was granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India.This PMS study continued to evaluate the safety and efficacy of Favipiravir (FabiFlu®) post its launch in the market. The average age of patients in the study was 40 years, with women comprising 40 per cent, while men 60 per cent of the study population. Hypertension (11 per cent) and diabetes (8 per cent) were the two most common comorbidities noted in these patients. Fever was present in all patients at baseline, followed by cough (81 per cent), fatigue (46.2 per cent), and new loss of taste (41 per cent).This story is provided by PRNewswire.will not be responsible in any way for the content of this article. (ANI/PRNewswire)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

GlenmarkFOLLOW

Glenmark, Latest News

Omega Healthcare Management Services ("Omega"), a leading provider of technology-enabled business process services across the healthcare ecosystem, announced today that Co-founder and current Chief Executive Officer Gopi Natarajan has decided to reti ...

With an objective to strengthen the direct consumer connect and give first-hand experience of existing and new product offerings, Vasu Healthcare, a leading brand in Herbal Cosmetics, Personal Care, Nutritional Supplements, has launched Company's fir ...

iEnergizer, a leading global Business Process Outsourcing (BPO) and IT-enabled services company based in Noida, has been declared a winner in the 2021 edition of Asia's Best Employer Brand Awards, supported by World HRD Congress. ...

The Income Tax department conducted searches on a pharmaceutical company in Hyderabad named Hetero Drugs and seized incriminating documents on Wednesday, sources told ANI. ...

New Delhi, Oct 5 Future 7-India Convenience Limited, Future Retails wholly owned subsidiary, and 7-Eleven Inc have mutually ... ...

TVS Motor Company registered sales growth of 6% with 347,156 units in September 2021 as against sales of 327,692 units in the month of September 2020. ...

Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc. ...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India. ...